<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749786</url>
  </required_header>
  <id_info>
    <org_study_id>22419</org_study_id>
    <nct_id>NCT02749786</nct_id>
  </id_info>
  <brief_title>Genetic Basis of Rosacea Study (Control)</brief_title>
  <official_title>Expansion Arm of Papulopustular Rosacea Gene Expression Profiling to Include Normal Individuals as Anatomic Site Specific Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rosacea is a common disease characterized by inflammation and vascular abnormalities of the
      facial skin and ocular surface. It it considered to be a syndrome encompassing various
      combinations of cutaneous signs including flushing, erythema, telangiectasia, papules, edema,
      ocular lesions, and rhinophyma. The exact etiology of cutaneous rosacea is unknown but is
      characterized by persistent vasodilation, increased vascular permeability, and vascular
      hyper-reactivity of the microcirculation of the central part of the face. The purpose of this
      study is to develop gene expression profiles of papulopustular rosacea compared to those of
      normal skin. The investigator hopes to better understand the abnormal gene functions that
      might contribute to this condition. This understanding may lead to the development of
      additional and better treatments for rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2016</start_date>
  <completion_date type="Actual">August 1, 2016</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression profile of papulopustular rosacea compared to normal skin and skin from individuals without rosacea.</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants who do not have rosacea (control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin Biopsy</intervention_name>
    <description>Skin biopsies will be performed via the Keys punch technique from normal facial skin.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria include:

          1. Fitzpatrick skin type II or III

          2. Age greater than or equal to 18 years

          3. Individuals without a history of rosacea

        Exclusion criteria include:

          1. Women who are pregnant or lactating

          2. Use of topical prescription medications or procedures to the face within one month of
             enrollment

          3. Skin conditions that might interfere with interpretation of procedure results (at the
             discretion of the investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Dermatology</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anne Chang</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

